Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis
New England Journal of Medicine2015Vol. 373(20), pp. 1986–1988
Citations Over TimeTop 1% of 2015 papers
Guido V. Bloemberg, Peter M. Keller, David Stucki, Andrej Trauner, Sònia Borrell, Tsogyal D. Latshang, Mireia Coscollá, Thomas Rothe, Rico Hömke, Claudia Ritter, Julia Feldmann, Bettina Schulthess, Sébastien Gagneux, Erik C. Böttger
Abstract
Treatment of multidrug-resistant Mycobacterium tuberculosis is a challenge. This letter describes the emergence of resistance to new therapies, bedaquiline and delamanid.
Related Papers
- → Emergence of bedaquiline resistance in a high tuberculosis burden country(2021)116 cited
- → A review of tuberculosis: Focus on bedaquiline(2013)41 cited
- → Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified?(2017)10 cited
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → Genentech taps Affimed’s antibodies(2018)